Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
People in jail, who are often in the system for less time than those in prison, often receive little to no hepatitis C screening or treatment. One provider works to change this in Massachusetts.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).
Sep. 5, 2019: An extra decade of "heart age"; stop grouping trans women with MSM; women often have anal cancer precursor lesions; hep C treatment success doesn't equal more risk behavior.
A new study puts numbers to increasingly divergent trends in liver-related deaths vs. injection-related deaths in recent years, highlighting both the success of modern HCV treatment and the devastating effects of the opioid crisis.
Although several HCV drugs can cure almost all infections regardless of viral genotype, picking the right drug will depend on each patient's medical history, level of liver damage, and coinfections.
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
The 548-person U.S. study found that chronic hepatitis C infection occurred among an identical number of people who received the experimental vaccine compared to people who received a placebo.
June 13, 2019: Integrated stepped alcohol treatment in HIV clinics; cytokines, inflammation, and heart risk; impact of CCR5 gene editing on lifespan; the costs of "test and treat" for hepatitis C.